Diabetes

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

The drug could also reduce chronic kidney disease when combined with insulin therapy.

Real-world effectiveness data showed semaglutide reduced the risk of major kidney disease events by 26%.

Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.

Patients who received pharmacist support reached their A1c goal 14 months sooner than those who did not receive the care.

For women in rural populations, access to education and care is limited, causing disparities in diabetes care.

Investigators find that the risk for new-onset diabetes is especially prominent for patients aged 20 to 29 years.

A modified DASH diet with lower sodium optimized for patients with type 2 diabetes reduced both systolic and diastolic blood pressure.

Hepatitis B and liver functions have been found to be independent risk factors for gestational diabetes and are found to have the highest prevalence of abnormalities.

Investigators found that longer durations of GLP-1 use were associated with increased risk of nAMD.

A significant number of patients remain unaware of their diabetes, signaling a need for better diagnostic efforts.

The associations and strengths of these links varied by the complication type, including diabetic nephropathy, neuropathy, and retinopathy.

Esaxerenone is a nonsteroidal mineralocorticoid receptor blocker that is being studied for its effectiveness for diabetes-associated mineralocorticoid receptor-related hypertension.

The results show promise, as vision typically improves the most during the first 4 weeks, but with lamivudine, vision continued to improve in the following 4 weeks.

Razanne Oueini, PharmD, MSc, CPHQ, discusses how rates of persistence to basal insulin were impacted after the IRA monthly cap.

Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.

Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.